Sculptor Capital LP Has $141.33 Million Stock Holdings in Bruker Corporation $BRKR

Sculptor Capital LP decreased its holdings in Bruker Corporation (NASDAQ:BRKR) by 2.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,000,000 shares of the medical research company’s stock after selling 74,801 shares during the quarter. Bruker accounts for approximately 1.4% of Sculptor Capital LP’s holdings, making the stock its 13th biggest holding. Sculptor Capital LP’s holdings in Bruker were worth $141,330,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Los Angeles Capital Management LLC acquired a new position in shares of Bruker in the 4th quarter valued at $26,000. Allworth Financial LP raised its stake in shares of Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after buying an additional 257 shares in the last quarter. Parallel Advisors LLC raised its stake in shares of Bruker by 121.0% in the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after buying an additional 479 shares in the last quarter. Covestor Ltd raised its stake in shares of Bruker by 304.6% in the 4th quarter. Covestor Ltd now owns 1,416 shares of the medical research company’s stock valued at $67,000 after buying an additional 1,066 shares in the last quarter. Finally, Parkside Financial Bank & Trust grew its holdings in shares of Bruker by 144.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,482 shares of the medical research company’s stock worth $70,000 after purchasing an additional 876 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Stock Performance

Bruker stock opened at $56.63 on Tuesday. The company has a current ratio of 1.55, a quick ratio of 0.72 and a debt-to-equity ratio of 0.67. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $64.54. The company has a market cap of $8.62 billion, a PE ratio of -235.96, a PEG ratio of 1.74 and a beta of 1.30. The company’s 50-day moving average is $45.01 and its two-hundred day moving average is $43.89.

Bruker (NASDAQ:BRKR) last released its earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The company had revenue of $823.40 million for the quarter, compared to the consensus estimate of $795.62 million. During the same period in the prior year, the company posted $0.47 EPS. The company’s revenue was up 2.7% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities analysts anticipate that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd will be given a dividend of $0.05 per share. The ex-dividend date is Monday, June 22nd. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. Bruker’s dividend payout ratio is presently -83.33%.

Insider Transactions at Bruker

In other Bruker news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total transaction of $79,800.00. Following the transaction, the vice president directly owned 128,443 shares in the company, valued at approximately $5,124,875.70. This represents a 1.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 27.20% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Wolfe Research assumed coverage on shares of Bruker in a report on Monday, June 1st. They issued a “peer perform” rating on the stock. Guggenheim lowered their target price on shares of Bruker from $58.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, March 30th. Barclays upped their target price on shares of Bruker from $45.00 to $53.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Weiss Ratings raised shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, June 3rd. Finally, UBS Group upped their target price on shares of Bruker from $40.00 to $45.00 and gave the stock a “neutral” rating in a report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $51.31.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.